Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial

Journal of the American Academy of Dermatology

Volumn 62, Issue 2, 2010, Pages 205-217

  Grant, Annika ^a   Gonzalez, Tayler ^b   Montgomery, Michael O ^b   Cardenas, Vanessa ^a   Kerdel, Francisco A ^a  

^a Florida Academic Dermatology Centers   (United States)

^b CENTOCOR INC   (United States)

Author keywords

hidradenitis suppurativa; infliximab; tumor necrosis factor

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FLU LIKE SYNDROME; HERPES SIMPLEX; HUMAN; HYPERTENSION; INFLAMMATION; MALE; MYALGIA; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUPPURATIVE HIDRADENITIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUBERCULOSIS; URTICARIA; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 73649148370     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.06.050     Document Type: Article

References (56)

1. Poli F., Jemec G.B.E., and Revuz J. Clinical presentation. In: Jemec G.B.E., Revuz J., and Leyden J.J. (Eds). Hidradenitis suppurativa (2006), Springer-Verlag, Heidelberg (Germany) 11-24
2. In: Jemec G.B.E., Revuz J., and Leyden J.J. (Eds). Hidradenitis suppurativa (2006), Springer-Verlag, Heidelberg (Germany)
3. Krbec A.C. Current understanding and management of hidradenitis suppurativa. J Am Acad Nurse Pract 19 (2007) 228-234
4. Gao M., Wang P.G., Cui Y., Yang S., Zhang Y.H., Lin D., et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol 126 (2006) 1302-1306
5. Von Der Werth J.M., Williams H.C., and Raeburn J.A. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 142 (2000) 947-953
6. Fitzsimmons J.S., Guilbert P.R., and Fitzsimmons E.M. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol 113 (1985) 1-8
7. Jemec G.B., Thomsen B.M., and Hansen U. The homogeneity of hidradenitis suppurativa lesions: a histological study of intra-individual variation. APMIS 105 (1997) 378-383
8. Jansen I., Altmeyer P., and Piewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol 15 (2001) 532-540
9. Oprica C., and Nord C.E. Bacteriology of hidradenitis suppurativa. In: Jemec G.B.E., Revuz J., and Leyden J.J. (Eds). Hidradenitis suppurativa (2006), Springer-Verlag, Heidelberg (Germany) 86-94
10. Boer J., and Weltevreden E.F. Hidradenitis suppurativa or acne inversa: a clinicopathological study of early lesions. Br J Dermatol 135 (1996) 721-725
11. Wolkenstein P., Loundou A., Barrau K., Auquier P., and Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 56 (2007) 621-623
12. von der Werth J.M., and Jemec G.B. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 144 (2001) 809-813
13. Harrison B.J., Mudge M., and Hughes L.E. The prevalence of hidradenitis suppurativa in South Wales. In: Marks R., and Plewig G. (Eds). Acne and related disorders (1988), Martin Dunitz Ltd, London pp. 365-66
14. Jemec G.B., Heidenheim M., and Nielsen N.H. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 35 (1996) 191-194
15. Jemec G.B. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 5 (2004) 1767-1770
16. Slade D.E., Powell B.W., and Mortimer P.S. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 56 (2003) 451-461
17. Kagan R.J., Yakuboff K.P., Warner P., and Warden G.D. Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery 138 (2005) 734-741
18. Rompel R., and Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 26 (2000) 638-643
19. Keating G.M., and Perry C.M. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 16 (2002) 111-148
20. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
21. Martinez F., Nos P., Benlloch S., and Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 7 (2001) 323-326
22. Katsanos K.H., Christodoulou D.K., and Tsianos E.V. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 97 (2002) 2155-2156
23. Gupta A.K., and Skinner A.R. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg 8 (2004) 77-89
24. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
25. Bhalla R., and Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis 53 (1994) 64-66
26. Rosi Y.L., Lowe L., and Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 16 (2005) 58-61
27. Roussomoustakaki M., Dimoulios P., Chatzicostas C., Kritikos H.D., Romanos J., Panayiotides J.G., et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 38 (2003) 1000-1004
28. Mekkes J.R., and Bos J.D. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 158 (2008) 370-374
29. Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., and Breathnach S.M. Localization of tumor necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94 (1993) 354-362
30. Hansen R.A., Gartlehner G., Powell G.E., and Sandler R.S. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 5 (2007) 729-735
31. Adams D.R., Gordon K.B., Devenyi A.G., and Ioffreda M.D. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 139 (2003) 1540-1542
32. Sullivan T.P., Welsh E., Kerdel F.A., Burdick A.E., and Kirsner R.S. Infliximab for hidradenitis suppurativa. Br J Dermatol 149 (2003) 1046-1049
33. Lebwohl B., and Sapadin A.N. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 49 Suppl (2003) S275-S276
34. Fardet L., Dupuy A., Kerob D., Levy A., Allez M., Begon E., et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 56 (2007) 624-628
35. Moschella S.L. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 46 (2007) 1287-1291
36. Drucker AM, Winkelman WJ, Walsh S, Shear NH. Long term experience with infliximab in hidradenitis suppurativa and pyroderma gangrenosum: a case series of 9 patients. Presented orally at: Canadian Dermatology Association 83rd Annual Conference, June 2008, Montreal.
37. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 366 (2005) 1367-1374
38. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56 (2007) e1-e15
39. Stern R., and Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 31 (2004) 1538-1545
40. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
41. Giamarellos-Bourboulis E.J., Antonopoulou A., Petropoulou C., Mouktaroudi M., Spyridaki E., Baziaka F., et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 156 (2007) 51-56
42. Price D.D., McGrath P.A., Rafii A., and Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17 (1983) 45-56
43. Fernandez-Vozmediano J.M., and Armario-Hita J.C. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 215 (2007) 41-44
44. Revuz J. Modifications to the Sartorius score and instructions for evaluating the severity of suppurative hidradenitis. Ann Dermatol Venereol 134 (2007) 173-174
45. Sartorius K., Lapins J., Emtestam L., and Jemec G.B. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 149 (2003) 211-213
46. Giamarellos-Bourboulis E.J., Pelekanou E., Antonopoulou A., Petropoulou H., Baziaka F., Karagianni V., et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 158 (2008) 567-572
47. Jemec G.B., and Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 39 (1998) 971-974
48. Mortimer P.S., Dawber R.P., Gales M.A., and Moore R.A. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed) 292 (1986) 245-248
49. Mortimer P.S., and Lunniss P.J. Hidradenitis suppurativa. J R Soc Med 93 (2000) 420-422
50. Revuz J. The role of surgery in the treatment of hidradenitis suppurativa. Ann Dermatol Venereol 135 (2008) 349-350
51. Buckley D.A., and Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 88 (1995) 289-90
52. Jemec G.B. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 27 (2002) 528-529
53. Cusack C., and Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 154 (2006) 726-729
54. Moul D.K., and Korman N.J. The cutting edge: severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 142 (2006) 1110-1112
55. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
56. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608